MeMed Gets $9.2M US Defense Contract

April 20, 2017 | MeMed, an Israeli start-up developing a reliable test to distinguish bacterial from viral infections, has secured a $9.2 million contract by the Defense Threat Reduction Agency (DTRA), a branch of the US Department of Defense (DoD) to improve clinical applications of its technology. The contract will fund the completion of MeMed’s pioneering point of care platform distinguishing bacterial from viral infections.  MeMed was founded in 2009 and is run by co-founder and CEO Eran Eden and co-founder and CTO Kfir Oved.